JP2017512194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512194A5 JP2017512194A5 JP2016553329A JP2016553329A JP2017512194A5 JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- fgf
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims 7
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 4
- 208000015100 cartilage disease Diseases 0.000 claims 3
- 206010061762 Chondropathy Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 210000001188 articular cartilage Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14000600 | 2014-02-20 | ||
| EP14000600.8 | 2014-02-20 | ||
| PCT/EP2015/053624 WO2015124727A1 (en) | 2014-02-20 | 2015-02-20 | Fgf-18 compound dosing regimen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512194A JP2017512194A (ja) | 2017-05-18 |
| JP2017512194A5 true JP2017512194A5 (enExample) | 2018-03-08 |
| JP6431083B2 JP6431083B2 (ja) | 2018-11-28 |
Family
ID=50151088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553284A Active JP6431082B2 (ja) | 2014-02-20 | 2015-02-20 | Ｆｇｆ−１８化合物の投与計画 |
| JP2016553329A Active JP6431083B2 (ja) | 2014-02-20 | 2015-02-20 | Ｆｇｆ−１８化合物の投与計画 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553284A Active JP6431082B2 (ja) | 2014-02-20 | 2015-02-20 | Ｆｇｆ−１８化合物の投与計画 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9889179B2 (enExample) |
| EP (2) | EP3119417B1 (enExample) |
| JP (2) | JP6431082B2 (enExample) |
| KR (2) | KR102410986B1 (enExample) |
| CN (2) | CN106232622A (enExample) |
| AR (2) | AR099510A1 (enExample) |
| AU (2) | AU2015220773B2 (enExample) |
| BR (2) | BR112016018685A2 (enExample) |
| CA (2) | CA2938793A1 (enExample) |
| DK (2) | DK3119417T3 (enExample) |
| ES (2) | ES2689071T3 (enExample) |
| HR (2) | HRP20181572T1 (enExample) |
| HU (1) | HUE040350T2 (enExample) |
| IL (2) | IL247084B (enExample) |
| LT (2) | LT3119417T (enExample) |
| MX (2) | MX2016010871A (enExample) |
| NZ (1) | NZ723148A (enExample) |
| PL (2) | PL3107559T3 (enExample) |
| PT (2) | PT3107559T (enExample) |
| RS (2) | RS57853B1 (enExample) |
| RU (2) | RU2691946C2 (enExample) |
| SG (2) | SG11201606505UA (enExample) |
| SI (2) | SI3119417T1 (enExample) |
| WO (2) | WO2015124731A1 (enExample) |
| ZA (2) | ZA201605548B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016018681B1 (pt) | 2014-02-20 | 2021-01-05 | Merck Patent Gmbh | sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura |
| EP3119417B1 (en) | 2014-02-20 | 2018-07-11 | Merck Patent GmbH | Fgf-18 compound dosing regimen |
| WO2016120387A1 (en) | 2015-01-29 | 2016-08-04 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| CN108697702A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| RS63292B1 (sr) * | 2017-09-29 | 2022-06-30 | Merck Patent Gmbh | Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18 |
| SI3687558T1 (sl) | 2017-09-29 | 2022-08-31 | Merck Patent Gmbh | Presnovni biooznačevalci za napovedovanje odzivnosti na spojino FGF-18 |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| JP7671249B2 (ja) * | 2019-02-08 | 2025-05-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 変形性関節症が急速に進行するリスクがある患者の治療 |
| WO2025077768A1 (en) * | 2023-10-11 | 2025-04-17 | Sichuan Real & Best Biotech Co., Ltd. | Compositions and methods for treating arthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279835B2 (en) * | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| ES2706848T3 (es) * | 2004-07-06 | 2019-04-01 | Zymogenetics Inc | Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso |
| WO2007070983A1 (en) * | 2005-12-22 | 2007-06-28 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| ES2392883T3 (es) * | 2006-08-25 | 2012-12-14 | Ares Trading S.A. | Tratamiento de trastornos de cartílagos con FGF-18 |
| HRP20120643T1 (hr) * | 2006-08-25 | 2012-08-31 | Ares Trading S.A. | Liječenje poremećaja hrskavice sa fgf-18 |
| DE102006043260A1 (de) * | 2006-09-11 | 2008-03-27 | Krones Ag | Etikettieranlage |
| BR112013024267A2 (pt) * | 2011-03-22 | 2018-06-26 | Advinus Therapeutics Ltd | compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos. |
| BR112016018681B1 (pt) | 2014-02-20 | 2021-01-05 | Merck Patent Gmbh | sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura |
| ES2676318T3 (es) | 2014-02-20 | 2018-07-18 | Merck Patent Gmbh | FGF-18 en procedimientos de trasplante de injertos y de ingeniería tisular |
| EP3119417B1 (en) | 2014-02-20 | 2018-07-11 | Merck Patent GmbH | Fgf-18 compound dosing regimen |
-
2015
- 2015-02-20 EP EP15707076.4A patent/EP3119417B1/en active Active
- 2015-02-20 SG SG11201606505UA patent/SG11201606505UA/en unknown
- 2015-02-20 LT LTEP15707076.4T patent/LT3119417T/lt unknown
- 2015-02-20 CN CN201580020536.2A patent/CN106232622A/zh active Pending
- 2015-02-20 EP EP15706006.2A patent/EP3107559B1/en active Active
- 2015-02-20 RU RU2016137289A patent/RU2691946C2/ru active
- 2015-02-20 PT PT15706006T patent/PT3107559T/pt unknown
- 2015-02-20 ES ES15706006.2T patent/ES2689071T3/es active Active
- 2015-02-20 HR HRP20181572TT patent/HRP20181572T1/hr unknown
- 2015-02-20 AU AU2015220773A patent/AU2015220773B2/en active Active
- 2015-02-20 US US15/120,131 patent/US9889179B2/en active Active
- 2015-02-20 CA CA2938793A patent/CA2938793A1/en active Pending
- 2015-02-20 SG SG11201606502YA patent/SG11201606502YA/en unknown
- 2015-02-20 US US15/120,134 patent/US9724388B2/en active Active
- 2015-02-20 CN CN201580020532.4A patent/CN106456713A/zh active Pending
- 2015-02-20 MX MX2016010871A patent/MX2016010871A/es active IP Right Grant
- 2015-02-20 ES ES15707076.4T patent/ES2688551T3/es active Active
- 2015-02-20 AR ARP150100508A patent/AR099510A1/es unknown
- 2015-02-20 WO PCT/EP2015/053631 patent/WO2015124731A1/en not_active Ceased
- 2015-02-20 JP JP2016553284A patent/JP6431082B2/ja active Active
- 2015-02-20 BR BR112016018685A patent/BR112016018685A2/pt not_active Application Discontinuation
- 2015-02-20 DK DK15707076.4T patent/DK3119417T3/en active
- 2015-02-20 JP JP2016553329A patent/JP6431083B2/ja active Active
- 2015-02-20 KR KR1020167025246A patent/KR102410986B1/ko active Active
- 2015-02-20 WO PCT/EP2015/053624 patent/WO2015124727A1/en not_active Ceased
- 2015-02-20 LT LTEP15706006.2T patent/LT3107559T/lt unknown
- 2015-02-20 AR ARP150100507A patent/AR099558A1/es unknown
- 2015-02-20 PL PL15706006T patent/PL3107559T3/pl unknown
- 2015-02-20 AU AU2015220777A patent/AU2015220777B2/en active Active
- 2015-02-20 KR KR1020167025245A patent/KR102410988B1/ko active Active
- 2015-02-20 PL PL15707076T patent/PL3119417T3/pl unknown
- 2015-02-20 CA CA2938791A patent/CA2938791A1/en not_active Abandoned
- 2015-02-20 HU HUE15706006A patent/HUE040350T2/hu unknown
- 2015-02-20 RS RS20181167A patent/RS57853B1/sr unknown
- 2015-02-20 NZ NZ723148A patent/NZ723148A/en unknown
- 2015-02-20 RU RU2016137292A patent/RU2700582C2/ru active
- 2015-02-20 DK DK15706006.2T patent/DK3107559T3/en active
- 2015-02-20 SI SI201530410T patent/SI3119417T1/sl unknown
- 2015-02-20 BR BR112016018696A patent/BR112016018696A2/pt not_active Application Discontinuation
- 2015-02-20 RS RS20181168A patent/RS57709B1/sr unknown
- 2015-02-20 HR HRP20181570TT patent/HRP20181570T1/hr unknown
- 2015-02-20 PT PT15707076T patent/PT3119417T/pt unknown
- 2015-02-20 SI SI201530428T patent/SI3107559T1/sl unknown
- 2015-02-20 MX MX2016010872A patent/MX2016010872A/es active IP Right Grant
-
2016
- 2016-08-03 IL IL247084A patent/IL247084B/en active IP Right Grant
- 2016-08-03 IL IL247083A patent/IL247083B/en active IP Right Grant
- 2016-08-10 ZA ZA2016/05548A patent/ZA201605548B/en unknown
- 2016-08-10 ZA ZA2016/05547A patent/ZA201605547B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512194A5 (enExample) | ||
| JP2017507142A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2015038135A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2015057451A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| JP2016530280A5 (enExample) | ||
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| MX2016010179A (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| RU2016137289A (ru) | Схема применения соединения fgf-18 | |
| WO2015171965A3 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2013541583A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| JP2016505050A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2018506533A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| JP2017061488A5 (enExample) | ||
| JP2017531042A5 (enExample) | ||
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice |